Polymyalgia Rheumatica Drug Pipeline Market Research Report 2021 Featuring Bristol-Myers Squibb, AbbVie, Eli Lilly and Co, & Sparrow Pharmaceuticals - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Polymyalgia Rheumatica - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Polymyalgia Rheumatica - Pipeline Insight, 2021" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Polymyalgia Rheumatica pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Polymyalgia Rheumatica R&D. The therapies under development are focused on novel approaches to treat/improve Polymyalgia Rheumatica.

Polymyalgia Rheumatica Emerging Drugs Chapters

This segment of the Polymyalgia Rheumatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polymyalgia Rheumatica Emerging Drugs

Tocilizumab: Chugai Pharmaceutical/Roche

Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 signal transduction to inflammatory mediators that summon B and T cells. Tocilizumab has a nonlinear pharmacokinetic profile. Tocilizumab is effective in cases of isolated PMR, particularly in combination with glucocorticoids. A Phase III clinical trial evaluated tocilizumab to treat Polymyalgia Rheumatica.

Polymyalgia Rheumatica: Therapeutic Assessment

This segment of the report provides insights about the different Polymyalgia Rheumatica drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polymyalgia Rheumatica

There are approx. 3+ key companies which are developing the therapies for Polymyalgia Rheumatica. The companies which have their Polymyalgia Rheumatica drug candidates in the most advanced stage, i.e. Phase III include, Chugai Pharmaceutical/Roche.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Polymyalgia Rheumatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polymyalgia Rheumatica: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polymyalgia Rheumatica therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polymyalgia Rheumatica drugs.

Polymyalgia Rheumatica Report Insights

• Polymyalgia Rheumatica Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polymyalgia Rheumatica Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

• How many companies are developing Polymyalgia Rheumatica drugs?
• How many Polymyalgia Rheumatica drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polymyalgia Rheumatica?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polymyalgia Rheumatica therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polymyalgia Rheumatica and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

• Bristol-Myers Squibb
• AbbVie
• Eli Lilly and Company
• Sparrow Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7mraff

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900